Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016
02 September 2016 - 10:30PM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of innovative
therapies to treat central nervous system (CNS) disorders, today
announced that it will present at the 23rd Annual NewsMakers in the
Biotech Industry conference in New York on Friday, September 9,
2016 at 1:30 p.m. eastern time.
The presentation will be webcast and accessible
through the investor relations section of the Company’s web site,
http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva’s proprietary compounds include: MIN-101,
which has completed Phase IIb development for schizophrenia;
MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib
clinical trials in insomnia and major depressive order (MDD),
respectively; MIN-117, which has completed Phase IIa development
for MDD; and MIN-301, in pre-clinical development for Parkinson’s
disease. Minerva’s common stock is listed on the NASDAQ
Global Market under the symbol “NERV.” For more information,
please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024